Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OBAID SHAIKH

NPI
1184699001
CMS profile
325436
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$5,805.48

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,540.00 1
Travel and Lodging $1,215.48 5
Food and Beverage $50.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $5,805.48 7

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OBAID SHAIKH

NPI 1184699001 · CMS profile ID 325436

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184699001?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OBAID SHAIKH, NPI 1184699001, CMS profile ID 325436. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184699001?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). OBAID SHAIKH, NPI 1184699001, CMS profile ID 325436. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184699001?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
OBAID SHAIKH, NPI 1184699001, CMS profile ID 325436, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1184699001?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $5,805.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $34.0012/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845844329 CMS
Gilead Sciences, Inc. $35.8412/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845844331 CMS
Gilead Sciences, Inc. $4,540.0012/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845883575 CMS
Gilead Sciences, Inc. $50.0012/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848276153 CMS
Gilead Sciences, Inc. $234.8012/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845844323 CMS
Gilead Sciences, Inc. $320.9212/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845844325 CMS
Gilead Sciences, Inc. $589.9212/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845844327 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $72.85 1
PY2020 $10,675.00 3
PY2021 $5,805.48 7
PY2025 $37.84 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $22,041.00 6
PY2024 Principal investigator $58,581.00 7
PY2022 Principal investigator $35,182.08 52
PY2021 Principal investigator $60,813.85 33
PY2020 Principal investigator $166,897.98 49
PY2019 Principal investigator $303,925.08 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

98 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $17,349.00 12/31/2019 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670127977
Principal investigator 1 Merit Medical Systems Inc $487.50 12/31/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality) No dispute reported 06/30/2026 655839119
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 12/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528171
Principal investigator 1 PFIZER INC. $920.40 12/12/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675059
Principal investigator 1 PFIZER INC. $306.80 12/05/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673705
Principal investigator 1 Mallinckrodt Enterprises LLC $1,804.30 11/30/2019 Non-covered Recipient Entity
VA PITTSBURGH HEALTHCARE SYSTEM
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703220585
Principal investigator 1 Mallinckrodt Enterprises LLC $7,144.02 11/30/2019 Non-covered Recipient Entity
VA PITTSBURGH HEALTHCARE SYSTEM
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703220587
Principal investigator 1 PFIZER INC. $2,600.00 11/28/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672333
Principal investigator 1 PFIZER INC. $613.60 11/28/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673129
Principal investigator 1 PFIZER INC. $2,600.00 11/28/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676161
Principal investigator 1 PFIZER INC. $250.00 11/28/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671677407
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 11/13/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676400206
Principal investigator 1 PFIZER INC. $1,050.40 11/13/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669943
Principal investigator 1 Gilead Sciences, Inc. $3,000.00 11/04/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528167
Principal investigator 1 Gilead Sciences, Inc. $1,325.00 10/23/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676400201
Principal investigator 1 PFIZER INC. $1,970.80 10/23/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676243
Principal investigator 1 PFIZER INC. $1,773.20 10/02/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673639
Principal investigator 1 Merit Medical Systems Inc $487.50 09/30/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality) No dispute reported 06/30/2026 655839115
Principal investigator 1 Shire North American Group Inc $2,943.00 09/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA No dispute reported 06/30/2026 679388937
Principal investigator 1 Shire North American Group Inc $590.06 09/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA No dispute reported 06/30/2026 679388939
Principal investigator 1 Shire North American Group Inc $500.00 09/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA No dispute reported 06/30/2026 679388943
Principal investigator 1 Shire North American Group Inc $1,500.00 09/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA No dispute reported 06/30/2026 679388947
Principal investigator 1 Shire North American Group Inc $1,500.00 09/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA No dispute reported 06/30/2026 679388949
Principal investigator 1 Shire North American Group Inc $2,000.00 09/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA No dispute reported 06/30/2026 679388951
Principal investigator 1 Shire North American Group Inc $7,000.00 09/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA No dispute reported 06/30/2026 679388953
Principal investigator 1 Allergan Inc. $773.30 09/19/2019 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670077145
Principal investigator 1 Gilead Sciences, Inc. $5,797.00 09/18/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528161
Principal investigator 1 PFIZER INC. $1,336.40 09/18/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671668299
Principal investigator 1 PFIZER INC. $2,100.80 09/11/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671668993
Principal investigator 1 Gilead Sciences, Inc. $3,000.00 09/04/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528157
Principal investigator 1 PFIZER INC. $306.80 08/28/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678641
Principal investigator 1 Allergan Inc. $1,414.55 08/22/2019 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670067979
Principal investigator 1 Gilead Sciences, Inc. $1,325.00 08/21/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676400197
Principal investigator 1 Gilead Sciences, Inc. $2,585.00 08/21/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528151
Principal investigator 1 PFIZER INC. $5,626.40 08/14/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671677543
Principal investigator 1 Gilead Sciences, Inc. $1,500.00 08/07/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528145
Principal investigator 1 Shire North American Group Inc $1,500.00 08/06/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS FIGARO UC 302 No dispute reported 06/30/2026 679388725
Principal investigator 1 Shire North American Group Inc $1,500.00 08/06/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS FIGARO UC 302 No dispute reported 06/30/2026 679388729
Principal investigator 1 Shire North American Group Inc $2,000.00 08/06/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATIONOF PITTSBURGH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS FIGARO UC 302 No dispute reported 06/30/2026 679388731
Principal investigator 1 Mallinckrodt Enterprises LLC $1,000.00 07/31/2019 Non-covered Recipient Entity
VA PITTSBURGH HEALTHCARE SYSTEM
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703219889
Principal investigator 1 PFIZER INC. $2,823.60 07/24/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642849
Principal investigator 1 Gilead Sciences, Inc. $1,413.00 07/17/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528141
Principal investigator 1 Allergan Inc. $2,836.70 07/09/2019 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670055556
Principal investigator 1 PFIZER INC. $4,139.20 07/02/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642817
Principal investigator 1 Mallinckrodt Enterprises LLC $500.00 06/30/2019 Non-covered Recipient Entity
VA PITTSBURGH HEALTHCARE SYSTEM
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703219763
Principal investigator 1 Merit Medical Systems Inc $1,300.00 06/30/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality) No dispute reported 06/30/2026 655839113
Principal investigator 1 PFIZER INC. $5,033.60 06/26/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642851
Principal investigator 1 Gilead Sciences, Inc. $3,000.00 06/24/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528137
Principal investigator 1 Shire North American Group Inc $7,000.00 06/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION
EFFICACY AND SAFETY OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE CROHNS DISEASE CARMEN CD 307 No dispute reported 06/30/2026 679388265
Principal investigator 1 Gilead Sciences, Inc. $1,335.00 06/19/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528125
Principal investigator 1 Gilead Sciences, Inc. $1,413.00 06/19/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528131
Principal investigator 1 Shire North American Group Inc $7,000.00 06/11/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION
EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN'S DISEASE No dispute reported 06/30/2026 679388209
Principal investigator 1 Mallinckrodt Enterprises LLC $2,000.00 05/31/2019 Non-covered Recipient Entity
VA PITTSBURGH HEALTHCARE SYSTEM
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703219635
Principal investigator 1 PFIZER INC. $5,340.40 05/29/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623387
Principal investigator 1 Gilead Sciences, Inc. $1,598.00 05/22/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528115
Principal investigator 1 Gilead Sciences, Inc. $2,670.00 05/22/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528119
Principal investigator 1 PFIZER INC. $1,029.60 05/15/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623423
Principal investigator 1 PFIZER INC. $1,029.60 05/08/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623385
Principal investigator 1 Allergan Inc. $773.30 05/07/2019 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670043465
Principal investigator 1 PFIZER INC. $5,007.60 05/01/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623421
Principal investigator 1 Merit Medical Systems Inc $1,950.00 04/30/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality) No dispute reported 06/30/2026 655839117
Principal investigator 1 Gilead Sciences, Inc. $818.00 04/17/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676400193
Principal investigator 1 Gilead Sciences, Inc. $1,413.00 04/17/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528105
Principal investigator 1 Gilead Sciences, Inc. $5,664.00 04/17/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528109
Principal investigator 1 PFIZER INC. $500.00 04/10/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623311
Principal investigator 1 PFIZER INC. $2,537.60 04/10/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623419
Principal investigator 1 Merit Medical Systems Inc $487.50 03/31/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality) No dispute reported 06/30/2026 655839111
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 03/27/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528099
Principal investigator 1 PFIZER INC. $9,921.60 03/27/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627619
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 03/25/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528093
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 03/25/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528097
Principal investigator 1 Gilead Sciences, Inc. $1,636.00 03/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676400191
Principal investigator 1 Gilead Sciences, Inc. $1,413.00 03/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528083
Principal investigator 1 Gilead Sciences, Inc. $9,696.00 03/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528087
Principal investigator 1 PFIZER INC. $2,366.00 03/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627655
Principal investigator 1 PFIZER INC. $2,230.80 03/13/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627621
Principal investigator 1 PFIZER INC. $1,487.20 03/04/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627653
Principal investigator 1 Allergan Inc. $1,216.00 02/26/2019 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670026847
Principal investigator 1 Gilead Sciences, Inc. $2,542.00 02/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528075
Principal investigator 1 Gilead Sciences, Inc. $2,867.00 02/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528079
Principal investigator 1 PFIZER INC. $215.00 02/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616299
Principal investigator 1 PFIZER INC. $8,673.60 02/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616835
Principal investigator 1 PFIZER INC. $5,000.00 02/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616865
Principal investigator 1 PFIZER INC. $1,250.00 02/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616905
Principal investigator 1 PFIZER INC. $1,000.00 02/20/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671618217
Principal investigator 1 PFIZER INC. $1,643.20 02/13/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616945
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 02/11/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528069
Principal investigator 1 PFIZER INC. $10,979.80 02/04/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671618361
Principal investigator 1 Allergan Inc. $5,256.35 01/29/2019 Non-covered Recipient Entity
VETERANS RSCH FOUNDATION OF PITTSBU
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670019741
Principal investigator 1 Gilead Sciences, Inc. $1,413.00 01/28/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676528060
Principal investigator 1 Gilead Sciences, Inc. $7,398.00 01/28/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528065
Principal investigator 1 PFIZER INC. $7,800.00 01/23/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616025
Principal investigator 1 PFIZER INC. $16,627.00 01/16/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616795
Principal investigator 1 PFIZER INC. $2,600.00 01/03/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616455
Principal investigator 1 PFIZER INC. $2,600.00 01/03/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616547
Principal investigator 1 PFIZER INC. $13,000.00 01/03/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616951
Principal investigator 1 PFIZER INC. $10,400.00 01/03/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671618207
Principal investigator 1 PFIZER INC. $2,600.00 01/03/2019 Non-covered Recipient Entity
VETERANS RESEARCH FOUNDATION OF PITTSBURGH
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671618329